Institutional members access full text with Ovid®

Share this article on:

A Rare Type of Secondary Cancer in a Child With Acute Lymphoblastic Leukemia: Malignant Fibrous Histiocytoma

İncesoy Özdemir, Sonay MD; Balkaya, Eda MD; Ören, Ayşe C. MD; Bozkurt, Ceyhun MD; Şahin, Gürses MD; Ünlü, Ramazan E. MD; Ertem, Ayşe U. MD

Journal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p e121–e124
doi: 10.1097/MPH.0b013e318290c65c
Online Articles: Clinical and Laboratory Observations

Secondary cancers which are related with treatment of childhood acute lymphoblastic leukemia (ALL) is a significant problem with longer term. For development of secondary cancer after treatment, the latency period varies between 5 and 10 years. In this case, a 13 year-old-boy diagnosed as high-risk ALL was treated with chemotherapy and prophylactic cranial radiotherapy at a dose of 1800 cGy. Six years after the end of treatment he developed a 5×5×4 cm mass at the right temporal region of the cranium. The mass was excised totally with clear surgical margin. Pathology of mass has been diagnosed as malignant fibrous histiocytoma (MFH), recently referred to as an undifferentiated pleomorphic sarcoma (UPS). After treatment of childhood ALL, reported cases of secondary MFH is extremely rare in the literature. Herein we present a case of MFH/UPS that developed as a secondary cancer 6 years after the end of ALL treatment.

*Department of Pediatric Oncology, Dr Sami Ulus Obstetrics and Pediatrics Training and Research Hospital

Department of Plastic Surgery, Ankara Numune Training and Research Hospital, Ankara, Turkey

The authors declare no conflict of interest.

Reprints: Sonay İncesoy Özdemir, MD, Department of Pediatric Oncology, Dr Sami Ulus Obstetrics and Pediatrics Training and Research Hospital, Altindağ 06080, Ankara, Turkey (e-mail: sincesoy@yahoo.co.uk).

Received November 6, 2012

Accepted March 3, 2013

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.